Medication comparison
Semaglutide vs Tirzepatide: Ingredients, Brands & Evidence
Compare semaglutide and tirzepatide as active ingredients across brands, receptor activity, approved uses, direct evidence, and comparison limits.
The short answer
Semaglutide and tirzepatide are active ingredients, not single interchangeable products. Semaglutide acts at GLP-1 receptors; tirzepatide acts at GIP and GLP-1 receptors. The right evidence depends on the brand, indication, formulation, dose, and population being discussed.
Semaglutide vs Tirzepatide at a glance
The biggest difference is single glp-1 receptor activity versus dual gip/glp-1 receptor activity across multiple brands. Milligram amounts across different active ingredients are not equivalent.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide[1,2,3,4] |
| Receptor activity | GLP-1 | GIP and GLP-1[1,2,3,4] |
| Brands in this guide | Ozempic and Wegovy | Mounjaro and Zepbound[1,2,3,4] |
| Diabetes-focused brand | Ozempic | Mounjaro[1,2,3,4] |
| Weight-management brand | Wegovy | Zepbound[1,2,3,4] |
| Formulations represented | Brand-dependent injection and oral forms | Weekly injection[1,2,3,4] |
| Dose conversion | No validated milligram conversion to tirzepatide | No validated milligram conversion to semaglutide[1,2,3,4] |
| Direct obesity evidence | Studied as weekly semaglutide injection | Studied as weekly tirzepatide injection[5] |
What the evidence can—and cannot—compare
Mechanism is an ingredient-level distinction
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. That mechanistic difference applies across their respective brands, but approved use, formulation, and dosing still belong to each product label.[1,2,3,4]
Brands determine approved uses
Ozempic and Mounjaro are centered on type 2 diabetes labeling. Wegovy and Zepbound include chronic weight-management labeling, with additional product-specific indications. An ingredient name alone is therefore not enough to answer whether a use is on-label.[1,2,3,4]
The direct comparison has a narrow, important scope
SURMOUNT-5 directly compared maximum tolerated weekly tirzepatide and semaglutide injections for 72 weeks in adults with obesity without diabetes. Mean weight reduction favored tirzepatide in that population. It did not compare all brands, oral semaglutide, diabetes outcomes, or every clinically relevant safety question.[5]
Ingredient evidence also includes indirect programs
Semaglutide STEP and tirzepatide SURMOUNT trials provide product-specific placebo-controlled evidence. Differences between those programs can generate hypotheses, but only a study that randomizes the same eligible population to both treatments can support a direct causal comparison.[6,7]
Questions for an ingredient-level discussion
Ask which brand and indication are under consideration; whether evidence comes from a direct trial, a separate placebo trial, or observational care; which formulation and dose were studied; whether the population matches your diagnosis; and which product-specific warning or monitoring issue matters in your history.[1,2,3,4]
May be best aligned with
Semaglutide
Understanding the evidence and labeled choices across semaglutide brands
- Multiple brands, formulations, and labeled uses
- Longer post-market experience
- Product-specific cardiovascular, kidney, adolescent, and MASH labeling
May be best aligned with
Tirzepatide
Understanding the evidence and labeled choices across tirzepatide brands
- Dual GIP/GLP-1 receptor activity
- Diabetes and weight-management brands
- Direct comparative obesity evidence against semaglutide injection
Consider these tradeoffs
- An ingredient comparison cannot substitute for reading the exact brand label
- The obesity head-to-head result does not compare Ozempic with Mounjaro for diabetes
- Separate placebo-controlled programs are indirect comparisons
- There is no safe do-it-yourself dose-conversion formula
Frequently asked questions
Is semaglutide the same thing as Wegovy?
Semaglutide is the active ingredient in multiple brands, including Wegovy and Ozempic. Each brand has its own formulation, labeling, dose schedule, and approved uses.
Is tirzepatide the same thing as Zepbound?
Tirzepatide is the active ingredient in Zepbound and Mounjaro. Zepbound and Mounjaro have different approved-use labeling even though the ingredient is shared.
Does SURMOUNT-5 compare every semaglutide and tirzepatide brand?
No. It directly studied weekly injections at maximum tolerated obesity-treatment doses in adults with obesity without diabetes. It should not be generalized to every brand, formulation, or diagnosis.
Sources
- Ozempic prescribing information — U.S. Food and Drug Administration (2026-05)
- Wegovy prescribing information — U.S. Food and Drug Administration (2025-12)
- Mounjaro prescribing information — U.S. Food and Drug Administration (2026-01)
- Zepbound prescribing information — U.S. Food and Drug Administration (2026-02)
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — New England Journal of Medicine (2025-05-11)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine (2021-02-10)
- Tirzepatide Once Weekly for the Treatment of Obesity — New England Journal of Medicine (2022-06-04)
Related guidance
Medication comparisons
Wegovy vs Zepbound: Evidence, Dosing & Safety Compared
Compare Wegovy and Zepbound by labeled use, mechanism, titration, direct head-to-head evidence, safety, and practical prescribing questions.
16 min read
GLP-1 basics
7 Common GLP-1 Myths, Explained
What evidence and current labeling actually say about willpower, permanence, safety, muscle and lifestyle change.
11 min read
GLP-1 basics
How GLP-1 Medications Work
A plain-language guide to appetite, digestion, blood sugar and the differences among incretin medications.
9 min read